This trial will test the safety and effectiveness of a new drug, ERAS-801, for people with a certain type of brain tumor.
4 Primary · 7 Secondary · Reporting Duration: Assessed up to 24 months from time of first dose
Experimental Treatment
90 Total Participants · 2 Treatment Groups
Primary Treatment: ERAS-801 · No Placebo Group · Phase 1
Age 18 - 99 · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Florida | 100.0% |
18 - 65 | 100.0% |
Did not meet criteria | 100.0% |